ArticleBMC nephrology2025
Use of tocilizumab to treat IgA nephropathy complicated by idiopathic multicentric Castleman disease: a case report.
Article in BMC nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIdiopathic multicentric Castleman disease (iMCD) is a rare polyclonal lymphoproliferative disorder characterised by excessive interleukin-6 (IL-6) production. Interleukin-6 is known to enhance the synthesis of galactose-deficient IgA1 (Gd-IgA1), contributing to the pathogenesis of IgA nephropathy (IgAN). Additionally, vascular endothelial growth factor (VEGF) is also upregulated by IL-6, further exacerbating glomerular injury. Tocilizumab (TCZ), an anti–IL-6 receptor antibody, has been shown to inhibit IL-6 signaling, potentially reducing Gd-IgA1 and VEGF levels. Here, we report a rare and unique case of IgAN associated with iMCD, in which renal function, urinary protein levels, and serological markers improved following the administration of TCZ. CASE PRESENTATION: A 35-year-old male initially presented with proteinuria and haematuria and was later diagnosed with iMCD through lymph node biopsy. A renal biopsy revealed features consistent with IgAN, including mesangial IgA and C3 deposition. Tocilizumab was initiated at a dose of 8 mg/kg biweekly. Following treatment, improvements were observed in serum creatinine (from 1.45 to 1.23 mg/dL) and proteinuria (from 1.18 to 0.17 g/day). Following TCZ administration, serum VEGF levels decreased from 1557 to 702 pg/mL, and Gd-IgA1 levels declined from 14.99 to 5.97 ng/mL, indicating that TCZ may have contributed to the suppression of disease activity.
conclusionThis case highlights the potential role of IL-6 inhibition in managing renal involvement in iMCD, particularly in cases complicated by IgAN. The reduction in serum Gd-IgA1 and VEGF levels following TCZ administration suggests a possible mechanism for renal protection. This report contributes valuable insights into treatment strategies for IgAN associated with iMCD and underscores the importance of considering IL-6–targeted therapy in similar cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.